From: Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Characteristic | Echinocandin | Fluconazole | P |
---|---|---|---|
(n = 315) | (n = 374) | ||
Antifungal exposure in preceding 30Â days | 164 (52%) | 143 (38%) | <.001 |
 Triazole exposure | 92 (29%) | 127 (34%) | .19 |
 Echinocandin exposure | 90 (29%) | 15 (4%) | <.001 |
Empiric therapy | 47 (15%) | 52 (14%) | .74 |
Delay between culture and treatment, days | 2.5 ± 1.4 | 2.2 ± 1.4 | .033 |
Months since PATH registry opened | 26 ± 11 | 23 ± 12 | <.001 |
Initial therapy changed by day 2 | 35 (11%) | 90 (24%) | <.001 |
Initial therapy changed by day 6 | 98 (31%) | 121 (32%) | .74 |